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Szmulewitz et al1 report a phase II noninferiority clinical trial
that compared the activity of low-dose abiraterone administered
with food (LOW) to the currently US Food and Drug Administration–
approved standard-dose abiraterone administered in the fasted
state (STD) in patients with castrate-resistant prostate cancer (CRPC).
Given that abiraterone commonly is used in the first-line setting of
CRPC and that its monthly cost is approximately $10,000, a 75% dose
reduction would entail substantial cost savings if the doses achieve
equivalent clinical outcomes.
The primary end point in this trial was prostate-specific antigen
(PSA) change between study entry and 12 weeks of therapy by
comparing the log-transformed mean change in PSA between the
STD and LOW groups. The LOW group had a mean log change
of 21.59 versus 21.19 in the STD group, which is sufficient to
establish the LOW group as noninferior to STD within a 90%
confidence limit. Although the prespecified noninferiority margin
of 15% was met, the clinical significance of the chosen end point is
unclear. As the authors acknowledge, log PSA change over 12 weeks
in not a clinically validated surrogate end point.
Reliance on local PSA testing in this trial is a substantial
concern, particularly given the noninferiority trial design the in-
vestigators chose. PSA results can vary by up to 20%2 for the same
sample, and the Prostate Cancer Working Group has recom-
mended central testing to minimize interassay variability.3 Of note,
the 20% variability in locally obtained PSA tests is greater than the
predetermined noninferiority margin of 15%. In addition, when
clinical trial end points are variable, the bias is toward the null
(ie, not detecting a difference). In a noninferiority trial design, failure
to reject the null establishes noninferiority of the treatments.4 In
other words, assay variability may lead to erroneously determining
two treatments to be noninferior. Given the large expected interassay
variation in PSA results, a conclusion of noninferiority in this trial
may be spurious.
Pharmacokinetic inferiority of the LOW group was demon-
strated, with significantly lower plasma trough and 2-hour postdose
(anticipatedmaximum serum concentration [Cmax]) concentrations
compared with the STD group. This finding contrasts an early
phase I study that demonstrated a significant food effect with
abiraterone5 but is consistent with more recent data.6 Subsequent
to abiraterone’s approval, definitive food-effect studies were con-
ducted in both healthy volunteers and patients with CRPC, al-
though published in the same article by Chi et al.6 In the relatively
young healthy volunteers who received a single dose of abiraterone
1,000 mg, significant differences in pharmacokinetic parameters
were noted among the fasted state, low-fat meal (an approximately
five-fold increase in the area under the curve), and high-fat meal
(approximately 10-fold increase in the area under the curve).
However, in the older patients with CRPC who received daily
abiraterone with pharmacokinetic parameters assessed on day 7,
no difference was found between the fasted state and low-fat meal,
and only an approximately two-fold increase was found with the
high-fat meal. Similar to the population and design of Chi et al,
patients studied by Szmulewitz et al1 were approximately the same
age and consumed a low-fat meal, and pharmacokinetics were
assessed at approximately the same time. Taken together, both
studies suggest a modest food effect of a low-fat meal in patients
with CRPC who take abiraterone chronically.
A Cmax of approximately 100 ng/mL in the STD group was
observed and seems lower than previously reported, where fasted
patients with CRPC who received 1,000 mg/d achieved a mean
Cmax of approximately 200 ng/mL.
6 This pharmacokinetic difference
may be related to the more real-world experience Szmulewitz et al1
studied. Chi et al6 served standard low- and high-fat breakfasts,
enforced fasting, and observed abiraterone administration on the
days of pharmacokinetic sampling. In contrast, patients in the
Szmulewitz et al study were instructed to eat a low-fat breakfast and
to take their medications. Although the patients completed pill and
diet diaries, nonadherence to study medications and dietary rec-
ommendations is common in clinical trials and may account for
the lower-than-expected plasma concentrations.
More importantly, are the pharmacokinetic parameters clin-
ically significant? A trough concentration of 8.4 ng/mL is associated
with PSA response, which is defined as a $ 50% reduction in PSA
at 12 weeks.7 In Szmulewitz et al,1 the LOW group had an average
trough concentration of approximately 2 ng/mL, whereas the STD
group had approximately 8 ng/mL. Although no association was
found between abiraterone trough concentration and PSA re-
sponse, the authors noted that the three individuals with the
highest trough concentrations had the best PSA responses. Of note,
the majority of patients in both the STD and the LOW groups had
trough abiraterone concentrations , 8.4 ng/mL. PSA responses
were similar between the LOW (58%) and STD (50%) groups and
generally consistent with a prior landmark trial (62%) by Ryan
et al.8 Progression-free survival (PFS) was similar between the
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LOWand STD groups at 8.6 months but seems inferior to the PFS
achieved with abiraterone in the landmark study at 16.5 months
and more similar to the placebo group at 8.3 months. Differences
in study population may account for the inferior PFS; in Szmulewitz
et al,1 11 patients received prior docetaxel and had a performance
status of 2, whereas Ryan et al8 allowed no prior therapy and
required a performance status of# 1. However, the contribution of
inadequate abiraterone concentrations to the poorer PFS observed
cannot be excluded.
In conclusion, we do not agree with the recommendation by
Szmulewitz et al1 that these data should be considered by prescribers,
payers, and patients when considering a dose-with-food strategy.
The evidence of noninferiority of the regimens is not compelling, the
evaluated primary end point is clinically questionable, and both
groups did not achieve an average trough abiraterone concentration
associated with clinical benefit. The overall poorer PFS observed in
this study combined with inadequate abiraterone trough con-
centrations in the STD group raises the question of suboptimal
adherence in the real world outside controlled clinical trials.
We suggest additional investigation of the target abiraterone
trough concentration predictive of response and consideration of
therapeutic drug monitoring (TDM) or determination of the target
plasma concentration of abiraterone and dosing to the target. TDM
is most useful for medications that are self-administered, with
narrow therapeutic indices, and high interpatient variability,9 and
abiraterone has all three characteristics. The overall goal of TDM is
to determine a significant association among drug dose, plasma
concentrations (pharmacokinetics), and pharmacodynamic re-
sponse. Plasma concentrations can be relatively easily and reliably
measured, and dose adjustments can achieve the desired con-
centration. TDM is routinely used in clinical practice for a number
of medications, including tacrolimus, but of note, use in oncology
is rare despite the deluge of targeted therapies. Determination of
the target plasma concentration of a drug during early-phase clinical
trials and development of an assay for drug concentration assess-
ment as a companion diagnostic may be a useful strategy to
minimize interpatient variability, assess adherence with oral medi-
cations, and improve efficacy.
Finally, the low-fat food effect of abiraterone in the target
population appears minimal at best and is close to moot as a novel
formulation of abiraterone without significant food effect in clinical
trials.10 We can only hope that the new formulation of abiraterone
will be priced more reasonably.
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